Circulation Reports最新文献_第7页

Transcriptome Discovery of Genes in the Three Phases of Autophagy That Are Upregulated During Atrial Fibrillation. 心房颤动期间自噬三个阶段上调基因的转录组学发现。

Circulation Reports Pub Date : 2023-04-10 DOI: 10.1253/circrep.CR-22-0130

Takahiro Kamihara, Akihiro Hirashiki, Manabu Kokubo, Atsuya Shimizu

{"title":"Transcriptome Discovery of Genes in the Three Phases of Autophagy That Are Upregulated During Atrial Fibrillation.","authors":"Takahiro Kamihara, Akihiro Hirashiki, Manabu Kokubo, Atsuya Shimizu","doi":"10.1253/circrep.CR-22-0130","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0130","url":null,"abstract":"Background: Autophagy may contribute to the maintenance of atrial fibrillation (AF), but no previous study has concurrently surveyed all 3 phases of autophagy, namely autophagosome formation, lysosome formation, and autophagosome-lysosome fusion. Here we aimed to identify disorders involving various phases of autophagy during AF. Methods and Results: We used bioinformatic techniques to analyze publicly available DNA microarray datasets from the left atrium (LA) and right atrium (RA) of 7 patients with AF and 6 patients with normal sinus rhythm who underwent valvular surgeries. We compared gene expression levels in the LA (AF-LA) and RA of patients with AF with those in the LA and RA of patients with normal sinus rhythm. Several differentially expressed genes in the AF-LA sample were significantly associated with the Gene Ontogeny term 'Autophagy', indicating that the expression of autophagic genes was specifically altered in this dataset. In particular, the expression of genes known or suspected to be involved in autophagosome formation (autophagy related 5 [ATG5], autophagy related 10 [ATG10], autophagy related 12 [ATG12], and light chain 3B [LC3B]), lysosome formation (lysosomal associated membrane protein 1 [LAMP1] and lysosomal associated membrane protein 2 [LAMP2]), and autophagosome-lysosome fusion (synaptosome associated protein 29 [SNAP29], SNAP associated protein [SNAPIN], and syntaxin 17 [STX17]) was significantly upregulated in the LA-AF dataset. Conclusions: Autophagy is activated excessively in, and may perpetuate, AF.","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 4","pages":"114-122"},"PeriodicalIF":0.0,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/fb/circrep-5-114.PMC10072901.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9272046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Cardiovascular Risk in Transgender People With Gender-Affirming Hormone Treatment. 变性人接受性别确认激素治疗的心血管风险

Circulation Reports Pub Date : 2023-04-10 DOI: 10.1253/circrep.CR-23-0021

Naoya Masumori, Mikiya Nakatsuka

{"title":"Cardiovascular Risk in Transgender People With Gender-Affirming Hormone Treatment.","authors":"Naoya Masumori, Mikiya Nakatsuka","doi":"10.1253/circrep.CR-23-0021","DOIUrl":"https://doi.org/10.1253/circrep.CR-23-0021","url":null,"abstract":"Gender-affirming hormone treatment generally by cross-sex hormones is an important strategy for transgender people to achieve the physical features affirming their experienced gender. Estrogens and androgens are administrated, usually for a long time, to transgender women and transgender men who would like to physically achieve feminization and masculinization, respectively. Several harmful adverse events have been reported in the literature following the administration of gender-affirming hormones, including worsening of lipid profiles and cardiovascular events (CVE) such as venous thromboembolism, stroke, and myocardial infarction, but it remains unknown whether the administration of cross-sex hormones to transgender people increases the subsequent risk of CVE and death. Based on the findings of the present narrative review of the recent literature, including meta-analyses and relatively large-scale cohort studies, it is likely that estrogen administration increases the risk of CVE in transgender women, but it remains inconclusive as to whether androgen administration increases the risk of CVE in transgender men. Thus, definitive evidence guaranteeing the long-term safety of cross-sex hormone treatment on the cardiovascular system is insufficient because of lack of evidence from well-organized, high-quality, and large-scale studies. In this situation, as well as considering the proper use of cross-sex hormones, pretreatment screening, regular medical monitoring, and appropriate intervention for risk factors of CVE are necessary to maintain and improve the health of transgender people.","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 4","pages":"105-113"},"PeriodicalIF":0.0,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/d1/circrep-5-105.PMC10072899.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9272043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Pneumopericardium Resulting After Pericardiocentesis. 心包穿刺后引起的心包气肿。

Circulation Reports Pub Date : 2023-04-10 DOI: 10.1253/circrep.CR-22-0061

Yuka Kawanami, Hiroshi Kawahara, Akihiro Endo, Hiroyuki Yoshitomi, Kazuaki Tanabe

引用次数: 0

Snare Technique Used to Pass a Navitor Transcatheter Heart Valve Through a Heavily Calcified Aortic Arch. 诱捕技术用于使经导管心脏瓣膜通过严重钙化的主动脉弓。

Circulation Reports Pub Date : 2023-04-10 DOI: 10.1253/circrep.CR-22-0132

Ryotaku Kawahata, Masanori Yamamoto, Ai Kagase, Takahiro Tokuda

引用次数: 0

Rationale and Design of the Effect of Ivabradine on Exercise Tolerance in Patients With Chronic Heart Failure (EXCILE-HF) Trial　- Protocol for a Multicenter Randomized Controlled Trial. 伊伐布雷定对慢性心力衰竭患者运动耐量影响的理论基础和设计(EXCILE-HF)试验-多中心随机对照试验方案

Circulation Reports Pub Date : 2023-04-10 DOI: 10.1253/circrep.CR-22-0134

Tsuyoshi Shiga, Tsuyoshi Suzuki, Keisuke Kida, Atsushi Suzuki, Takashi Kohno, Akiko Ushijima, Shunsuke Kiuchi, Shunsuke Ishii, Makoto Murata, Takeshi Ijichi, Makoto Suzuki, Masako Nishikawa

{"title":"Rationale and Design of the Effect of Ivabradine on Exercise Tolerance in Patients With Chronic Heart Failure (EXCILE-HF) Trial　- Protocol for a Multicenter Randomized Controlled Trial.","authors":"Tsuyoshi Shiga, Tsuyoshi Suzuki, Keisuke Kida, Atsushi Suzuki, Takashi Kohno, Akiko Ushijima, Shunsuke Kiuchi, Shunsuke Ishii, Makoto Murata, Takeshi Ijichi, Makoto Suzuki, Masako Nishikawa","doi":"10.1253/circrep.CR-22-0134","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0134","url":null,"abstract":"Background: A high resting heart rate is an independent risk factor for mortality and morbidity in patients with cardiovascular diseases. Ivabradine selectively inhibits the funny current (I f) and decreases heart rate without affecting cardiac conduction, contractility, or blood pressure. The effect of ivabradine on exercise tolerance in patients with heart failure with reduced ejection fraction (HFrEF) on standard drug therapies remains unclear. Methods and Results: This multicenter interventional trial of patients with HFrEF and a resting heart rate ≥75 beats/min in sinus rhythm treated with standard drug therapies will consist of 2 periods: a 12-week open-label, randomized, parallel-group intervention period (standard drug treatment+ivabradine group and standard drug treatment group) to compare changes in exercise tolerance between the 2 groups; and a 12-week open-label ivabradine treatment period for all patients to evaluate the effect of adding ivabradine on exercise tolerance. The primary endpoint will be the change in peak oxygen uptake (V̇O2) during the cardiopulmonary exercise test from Week 0 (baseline) to Week 12. Secondary endpoints will be time-dependent changes in peak V̇O2 from Week 0 to Weeks 12 and 24. Adverse events will also be evaluated. Conclusions: The EXCILE-HF trial will provide meaningful information regarding the effects of ivabradine on exercise tolerance in patients with HFrEF receiving standard drug therapies and suggestions for the initiation of ivabradine treatment.","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 4","pages":"157-161"},"PeriodicalIF":0.0,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/23/circrep-5-157.PMC10072898.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9265806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevention of Contrast-Induced Nephropathy After Emergency Percutaneous Coronary Intervention With a Single Bolus Administration of High-Concentrate Sodium Bicarbonate　- Rationale and Design of a Single-Arm Study Compared With Historical Controls. 单次注射高浓度碳酸氢钠预防急诊经皮冠状动脉介入术后造影剂肾病——与历史对照比较的单臂研究的原理和设计

Circulation Reports Pub Date : 2023-04-10 DOI: 10.1253/circrep.CR-22-0105

Takuya Nakamura, Makoto Watanabe, Kazutaka Nogi, Takaaki Kosugi, Yukihiro Hashimoto, Tomoya Ueda, Naofumi Doi, Hiroyuki Kawata, Manabu Horii, Kenichi Ishigami, Tamio Nakajima, Hiroaki Watabe, Daisuke Abe, Koichiro Kuwahara, Yasuo Okumura, Naoki Ozu, Shota Suzuki, Shu Kasama, Yoshihiko Saito

{"title":"Prevention of Contrast-Induced Nephropathy After Emergency Percutaneous Coronary Intervention With a Single Bolus Administration of High-Concentrate Sodium Bicarbonate　- Rationale and Design of a Single-Arm Study Compared With Historical Controls.","authors":"Takuya Nakamura, Makoto Watanabe, Kazutaka Nogi, Takaaki Kosugi, Yukihiro Hashimoto, Tomoya Ueda, Naofumi Doi, Hiroyuki Kawata, Manabu Horii, Kenichi Ishigami, Tamio Nakajima, Hiroaki Watabe, Daisuke Abe, Koichiro Kuwahara, Yasuo Okumura, Naoki Ozu, Shota Suzuki, Shu Kasama, Yoshihiko Saito","doi":"10.1253/circrep.CR-22-0105","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0105","url":null,"abstract":"Background: Contrast-induced nephropathy (CIN) is clinically important because of its poor prognosis. The incidence of CIN is higher in emergency than elective percutaneous coronary intervention (PCI) because there is no established method to prevent CIN. The aim of this study is to evaluate whether bolus administration of a concentrated solution of sodium bicarbonate can prevent CIN in patients undergoing emergency PCI. Methods and Results: This multicenter prospective single-arm trial with historical controls will include patients who are aged ≥20 years and will undergo cardiac catheterization for suspected acute myocardial infarction (AMI). Patients will receive an intravenous bolus administration of concentrated sodium bicarbonate solution (7% or 8.4%, 20 mEq) and will be observed for 72±12 h. Data for the control group, comprising all patients who underwent PCI for AMI between January 1, 2020 and December 31, 2020 across participating hospitals, will be extracted. The primary endpoint is the incidence of CIN, defined as an increase in serum creatinine of >0.5 mg/dL or >25% from baseline within 48±12 h. We will evaluate the endpoints in the prospective group and compare them with those in the historical control group. Conclusions: This study will evaluate whether a single bolus administration of concentrated sodium bicarbonate can prevent CIN after emergency PCI.","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 4","pages":"152-156"},"PeriodicalIF":0.0,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/4e/circrep-5-152.PMC10072897.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9272044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Content 内容

Circulation Reports Pub Date : 2023-04-10 DOI: 10.1253/circrep.cr-5-content4

引用次数: 0

Web-Based Questionnaire Survey on Heart Failure in Elderly Patients Using Outpatient Rehabilitation　- Actual Conditions of Cardiac Rehabilitation in Long-Term Care Insurance Systems. 基于网络的门诊康复老年患者心力衰竭问卷调查——长期护理保险系统心脏康复的实际情况。

Circulation Reports Pub Date : 2023-04-10 DOI: 10.1253/circrep.CR-22-0102

Yuta Tauchi, Tomoyuki Ogino, Tomoyuki Morisawa, Yosuke Wada, Rie Sakamoto, Yoshihiro Kanata, Kazuhisa Domen

{"title":"Web-Based Questionnaire Survey on Heart Failure in Elderly Patients Using Outpatient Rehabilitation　- Actual Conditions of Cardiac Rehabilitation in Long-Term Care Insurance Systems.","authors":"Yuta Tauchi, Tomoyuki Ogino, Tomoyuki Morisawa, Yosuke Wada, Rie Sakamoto, Yoshihiro Kanata, Kazuhisa Domen","doi":"10.1253/circrep.CR-22-0102","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0102","url":null,"abstract":"Background: The purpose of this study was to investigate the actual conditions of cardiac rehabilitation (CR) for elderly patients with heart failure (HF) in outpatient rehabilitation (OR) facilities using long-term care insurance systems. Methods and Results: This was a cross-sectional web-based questionnaire survey conducted at 1,258 facilities in the Kansai region (6 prefectures) of Japan from October to December 2021. In all, 184 facilities responded to the web-based questionnaire (response rate 14.8%). Of these facilities, 159 (86.4%) accepted patients with HF. Among the patients with HF, 94.3% were aged ≥75 years and 66.7% were classified as New York Heart Association functional class I/II. Facilities treating patients with HF generally provided exercise therapy, patient education, and disease management, which were components of CR. Many facilities not currently treating patients with HF responded positively stating they will accept HF patients in the future. However, a few facilities responded by stating that they are waiting for clearer evidence demonstrating the beneficial effect of OR on patients with HF. Conclusions: The present results show the possibility that outpatient CR can be performed for elderly patients with HF in other than medical insurance.","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 4","pages":"133-143"},"PeriodicalIF":0.0,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/ea/circrep-5-133.PMC10072896.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9260488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Longitudinal Stent Elongation Due to Inappropriate Post-Dilatation　- Insight From a Bench Test. 由于扩张后不适当导致的纵向支架伸长率——从台架试验中观察。

Circulation Reports Pub Date : 2023-04-04 eCollection Date: 2023-05-10 DOI: 10.1253/circrep.CR-23-0026

Hiroyuki Yamamoto, Shinsuke Nakano, Takayuki Saito, Tomofumi Takaya

引用次数: 0

Association of Left Atrial Size With Stroke or Systemic Embolism in Patients With Atrial Fibrillation Having Undergone Bioprosthetic Valve Replacement From the BPV-AF Registry. 接受BPV-AF登记的生物瓣膜置换术的心房颤动患者左心房大小与中风或系统性栓塞的关系。

Circulation Reports Pub Date : 2023-04-04 eCollection Date: 2023-05-10 DOI: 10.1253/circrep.CR-23-0007

Hidekazu Tanaka, Misa Takegami, Makoto Miyake, Masashi Amano, Takeshi Kitai, Tomoyuki Fujita, Tadaaki Koyama, Kenji Ando, Tatsuhiko Komiya, Masaki Izumo, Hiroya Kawai, Kiyoyuki Eishi, Kiyoshi Yoshida, Takeshi Kimura, Ryuzo Nawada, Tomohiro Sakamoto, Yoshisato Shibata, Toshihiro Fukui, Kenji Minatoya, Kenichi Tsujita, Yasushi Sakata, Tetsuya Kimura, Kunihiro Nishimura, Yutaka Furukawa, Chisato Izumi

{"title":"Association of Left Atrial Size With Stroke or Systemic Embolism in Patients With Atrial Fibrillation Having Undergone Bioprosthetic Valve Replacement From the BPV-AF Registry.","authors":"Hidekazu Tanaka, Misa Takegami, Makoto Miyake, Masashi Amano, Takeshi Kitai, Tomoyuki Fujita, Tadaaki Koyama, Kenji Ando, Tatsuhiko Komiya, Masaki Izumo, Hiroya Kawai, Kiyoyuki Eishi, Kiyoshi Yoshida, Takeshi Kimura, Ryuzo Nawada, Tomohiro Sakamoto, Yoshisato Shibata, Toshihiro Fukui, Kenji Minatoya, Kenichi Tsujita, Yasushi Sakata, Tetsuya Kimura, Kunihiro Nishimura, Yutaka Furukawa, Chisato Izumi","doi":"10.1253/circrep.CR-23-0007","DOIUrl":"10.1253/circrep.CR-23-0007","url":null,"abstract":"Background: The left atrial volume index (LAVI) is important for predicting thromboembolism in patients with non-valvular atrial fibrillation (AF), but the utility of LAVI for predicting thromboembolism in patients with both bioprosthetic valve replacement and AF remains unclear. Methods and Results: Of 894 patients from a previous multicenter prospective observational registry (BPV-AF Registry), 533 whose LAVI data had been obtained by transthoracic echocardiography were included in this subanalysis. Patients were divided into tertiles (T1-T3) according to LAVI as follows: T1 (n=177), LAVI=21.5-55.3 mL/m2; T2 (n=178), LAVI=55.6-82.1 mL/m2; T3 (n=178), LAVI=82.5-408.0 mL/m2. The primary outcome was defined as either stroke or systemic embolism for a mean (±SD) follow-up period of 15.3±4.2 months. Kaplan-Meier curves indicated that the primary outcome tended to occur more frequently in the group with the larger LAVI (log-rank P=0.098). Comparison of T1 with T2 plus T3 using Kaplan-Meier curves indicated that patients in T1 experienced significantly fewer primary outcomes (log-rank P=0.028). Furthermore, univariate Cox proportional hazard regression showed that 1.3- and 3.3-fold more primary outcomes occurred in T2 and T3, respectively, than in T1. Conclusions: Larger LAVI was associated with stroke or systemic embolism in patients who had undergone bioprosthetic valve replacement and with a definitive diagnosis of AF.","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 5","pages":"210-216"},"PeriodicalIF":0.0,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1d/7a/circrep-5-210.PMC10166667.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0